Amgen AMGN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Aranesp | $311M-6.6% | $333M-6.7% | $357M-0.6% | $359M+5.6% | $340M+10.4% | |
| BLINCYTO | $415M+0.5% | $413M+5.4% | $392M+2.1% | $384M+3.8% | $370M-2.9% | |
| ENBREL | $320M-39.8% | $532M-8.3% | $580M-4.0% | $604M+18.4% | $510M-49.8% | |
| EVENITY | $562M-6.2% | $599M+10.7% | $541M+4.4% | $518M+17.2% | $442M+2.6% | |
| IMDELLTRA/IMDYLLTRA | $258M— | —— | —— | —— | $81M— | |
| KRYSTEXXA | $255M-41.4% | $435M+35.9% | $320M-8.3% | $349M+47.9% | $236M-31.8% | |
| KYPROLIS | $330M-6.0% | $351M-2.2% | $359M-5.0% | $378M+16.7% | $324M-12.9% | |
| Nplate | $412M+7.0% | $385M-15.8% | $457M+23.8% | $369M+17.9% | $313M-7.1% | |
| Otezla | $431M-31.0% | $625M+6.8% | $585M-5.3% | $618M+41.4% | $437M-30.0% | |
| Other products | $1.53B-26.3% | $2.07B+11.9% | $1.85B+9.6% | $1.69B+14.6% | $1.48B-5.9% | |
| Prolia | $727M-31.0% | $1.05B-7.5% | $1.14B+1.5% | $1.12B+2.1% | $1.1B-5.7% | |
| Repatha | $876M— | —— | $794M+14.1% | $696M+6.1% | $656M+8.3% | |
| TEPEZZA | $490M+7.2% | $457M-18.4% | $560M+10.9% | $505M+32.5% | $381M-17.2% | |
| TEZSPIRE | $343M-27.6% | $474M+25.7% | $377M+10.2% | $342M+20.0% | $285M-3.7% | |
| UPLIZNA | $262M— | —— | —— | —— | $91M— | |
| Vectibix | $287M-10.0% | $319M+12.3% | $284M-6.9% | $305M+14.2% | $267M+8.5% | |
| XGEVA | $411M-8.1% | $447M-17.1% | $539M+1.3% | $532M-6.0% | $566M+0.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amgen break its business down?
- Amgen (AMGN) reports total revenues by product across 18 parts — Aranesp, BLINCYTO, ENBREL, EVENITY and IMDELLTRA/IMDYLLTRA. Each is extracted from the segment footnotes and tracked over time.
- Where does Amgen's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amgen's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
